Omidubicel

奥米珂赛

Report date: 2026/02/14 20:00:22

Base Information

Drug NameOmidubicel
Drug Alias NameUC MSCUmbilical cord blood stem cell therapy (Gamida Cell)CordInNAM-enabled stem cell therapy(Gamida Cell)omidubicel-onlv +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesThalassemiaAnemia, Sickle Cell +[13] 
Global Approved IndicationsInfections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/04/17
Country/TerritoryUnited StatesSingaporePortugal +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGamida Cell Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoslinCTGamida Cell IncAriti Sa +[5] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesAnemia, AplasticHematologic Neoplasms +[9] 
Inactive IndicationsThalassemiaAnemia, Sickle CellLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksN/A